FDA
-
-
-
-
-
-
-
Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML
-
-
-
-
-
-
-
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
-
-
-
-
-
-
-
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones
-
-
-
-
-
-
-
KOMZIFTI added to NCCN guidelines for relapsed AML treatment
-
-
-
-
-
-
-
Kura Oncology and Kyowa Kirin begin trial combining cancer drugs for AML
-
-
-
-
-
-
-
Guggenheim Starts Kura Oncology (KURA) at Neutral
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

